AIM Vaccine Co., Ltd. (HKG: 6660)

Market Cap	7.44B
Revenue (ttm)	1.27B
Net Income (ttm)	-1.28B
Shares Out	1.21B
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	927,600
Open	6.30
Previous Close	6.24
Day's Range	6.10 - 6.30
52-Week Range	3.95 - 15.48
Beta	-0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About AIM Vaccine

AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase IV clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine which is in phase III clinical trials to treat COVID-19 inf...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 1,624
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6660

Financial Performance

In 2023, AIM Vaccine's revenue was 1.19 billion, a decrease of -6.06% compared to the previous year's 1.26 billion. Losses were -1.30 billion, 307.1% more than in 2022.

Financial numbers in CNY